Goals of ProsTIC's theranostics research in prostate cancer
“We hope to further investigate next-generation PSMA-targeting molecules, develop new biomarkers to try to predict and monitor response to these novel therapies, optimize combinations with other treatments, and do some discovery research, including artificial intelligence [and] deep learning of our images,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.
In this video, Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS, discusses the goals and initiatives of the Prostate Cancer Theranostics and Imaging Center of Excellence (ProsTIC). Hofman is a nuclear medicine physician and director of ProsTIC, Melbourne, Australia.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
